PetIQ, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Revises Earnings Guidance for the Full Year 2024
May 08, 2024 at 04:05 pm EDT
Share
PetIQ, Inc. provided earnings guidance for the second quarter of 2024 and revised earnings guidance for the full year 2024. For the quarter, the company expects Net sales of $325.0 million to $335.0 million.
For the year, the company expects Net sales of $1,135.0 million to $1,185.0 million.
PetIQ, Inc. is a pet medication and wellness company, which provides veterinary products and services. The Company operates through two segments: Products and Services. Products segment manufactures and distributes pet medication and health and wellness products to major United States retail and e-commerce channels through more than 60,000 points of distribution. It is focused its offerings on value-branded products, and third-party branded products for dogs and cats, including pet Rx medications, OTC medications, and wellness products. Services segment provides a comprehensive suite of services at approximately 2,600 community clinic locations and wellness centers hosted at retailers across 39 states. The segmentâs services include diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene and wellness checks. The Rx pet medications products include flea and tick control, heartworm preventatives, arthritis, thyroid, and other specialty medications.
PETIQ, INC. 
